- Home
- CTSO
as 05-09-2025 4:00pm EST
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Upcoming Earnings Alert:
Get ready for potential market movements as Cytosorbents Corporation CTSO prepares to release earnings report on 14 May 2025.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 68.2M | IPO Year: | N/A |
| Target Price: | $4.67 | AVG Volume (30 days): | 138.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $1.61 | Next Earning Date: | 05-14-2025 |
| Revenue: | $35,594,520 | Revenue Growth: | 14.51% |
| Revenue Growth (this year): | 18.72% | Revenue Growth (next year): | 19.75% |
Latest Cytosorbents Corporation News
CTSO Breaking Stock News: Dive into CTSO Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
2 days ago
CTSO: CytoSorbents provides regulatory update for DrugSorb-ATR.
PR Newswire
8 days ago
CytoSorbents Provides Regulatory Update for DrugSorb-ATR
PR Newswire
11 days ago
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights
PR Newswire
19 days ago
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
PR Newswire
23 days ago
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
PR Newswire
a month ago
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
PR Newswire
a month ago
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
Zacks Small Cap Research
a month ago
CTSO: CytoSorbents Reports 4th quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations.
Compare CTSO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTSO Cytosorbents Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.